Current Price
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new drugs for inflammatory disorders, autoimmune diseases, and cancer in the United States. The company...|
e.g. Promoter holding
Loading chart...
Analyst consensus EPS and Revenue forecasts.
Earnings estimates are not available for this company.
| S.No. | Name | Symbol | Market Cap | P/E | P/B | Profit Margin | Op. Margin | ROE | Rev. Growth |
|---|---|---|---|---|---|---|---|---|---|
| 1. | BBain Capit... | BCSS | $598.60M | — | — | — | — | — | — |
| 2. | CChurchill... | CXII | $582.16M | — | — | — | — | — | — |
| 3. | CChurchill... | CCCX | $711.00M | — | 1.86 | — | — | — | — |
| 4. | CChurchill... | CCCX | $711.00M | — | 1.86 | — | — | — | — |
| 5. | AAmerican E... | AEXA | $533.68M | — | — | — | — | — | — |
Consolidated Figures in Millions / View Standalone.
| Quarter (M) | Dec 21 | Mar 22 | Jun 22 | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 |
|---|---|---|---|---|---|---|---|---|
Revenue | 2.61 | 5.46 | 11.76 | 0 | 0 | 0 | 0 | 0 |
COGS | 0.3 | 0.2 | 0.8 | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 2.31 | 5.25 | 10.96 | 0 | 0 | 0 | 0 | 0 |
Gross Profit % | 88.43% | 96.24% | 93.17% | - | - | - | - | - |
| 42.66 | 43.49 | 42.53 | 0.02 | 0.03 | 0.12 | 0.01 | 39.77 | |
EBIT | -40.05 | -38.23 | -31.57 | -0.02 | -0.05 | -0.12 | -0.01 | -39.77 |
OPM % | -1533.93% | -700.37% | -268.42% | - | - | - | - | - |
Non-Operating Income | -0.48 | -0.38 | -0.08 | 0 | 0 | 0 | 0.09 | 0 |
PBT | -40.53 | -38.61 | -31.65 | -0.02 | -0.05 | 0.43 | 0.08 | -134.68 |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Tax Rate % | - | - | - | - | - | - | - | - |
Net Income | -40.53 | -38.61 | -31.65 | -0.02 | -0.03 | 0.43 | 0.08 | -134.68 |
NPM % | -1552.2% | -707.24% | -269.07% | - | - | - | - | - |
Consolidated Figures in Millions / View Standalone.
| Period (M) | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 6.06 | 0 | 0 | 11.44 | 82.5 | 42.88 | 35.95 | 64.89 | 32.22 | 0 |
COGS | 44.6 | 33.81 | 33.18 | 37.95 | 49.49 | 62.74 | 70.28 | 0 | 0.3 | 0 |
Gross Profit | 6.06 | -33.81 | -33.18 | 11.94 | 82.5 | 42.88 | 36.13 | 64.89 | 31.92 | 0 |
Gross Profit % | 100% | - | - | 104.37% | 100% | 100% | 100.49% | 100% | 99.06% | - |
| 45.17 | 47.4 | 47.69 | 52.16 | 66 | 83.14 | 94.25 | 120.07 | 162.14 | 0.17 | |
EBIT | -39.12 | -47.4 | -47.69 | -40.72 | 16.49 | -40.27 | -58.3 | -55.18 | -129.92 | -0.17 |
OPM % | -645.46% | - | - | -356.1% | 19.99% | -93.92% | -162.17% | -85.03% | -403.17% | - |
Non-Operating Income | 0.44 | 0.47 | 0.38 | 0.76 | 1.37 | 2.3 | 2.81 | -0.18 | -1.84 | 0 |
PBT | -38.67 | -46.93 | -47.3 | -39.96 | 17.86 | -37.97 | -55.49 | -55.36 | -131.75 | 0.38 |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | - | - | - | - |
Net Income | -38.67 | -46.93 | -47.3 | -39.96 | 17.86 | -37.97 | -55.49 | -55.36 | -131.75 | 0.38 |
NPM % | -638.17% | - | - | -349.48% | 21.65% | -88.55% | -154.34% | -85.31% | -408.87% | - |
Consolidated Figures in Millions / View Standalone.
| Period (M) | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 10.26 | 16.07 | 12.82 | 12.02 | 40.02 | 28.09 | 39.18 | 32.3 | 49.98 | 0.74 | |
| 139.62 | 98.55 | 63.47 | 111.74 | 95.2 | 148.9 | 163.06 | 428.07 | 312.37 | 0 | |
| 1.4 | 1.21 | 0.95 | 0.91 | 1.21 | 1.54 | 2.15 | 25.16 | 32.27 | 0 | |
| 0.99 | 31.18 | 0.76 | 30.93 | 52.54 | 4.4 | 1.58 | 5 | 4.68 | 0.33 | |
| 0.16 | -30.02 | 0.16 | 0.28 | 0.36 | 0.39 | 3.11 | 28.37 | 26.35 | 414.85 | |
Total Assets | 152.42 | 116.98 | 78.16 | 155.87 | 189.33 | 183.31 | 209.08 | 518.9 | 425.65 | 415.91 |
| -145.26 | 0.04 | 0.04 | 0.05 | 0.05 | 0.05 | 0.06 | 0.07 | 0.07 | 414 | |
| 290.57 | 108.56 | 72.46 | 49.84 | 79.22 | 14.69 | 65.94 | 385.54 | 286.05 | -14.21 | |
| 0.33 | 0 | 0 | 0 | 91.95 | 168.59 | 21.29 | 63.92 | 23.64 | 0 | |
| 6.56 | 8.19 | 5.49 | 9.32 | 9.97 | 13.94 | 19.84 | 31.82 | 33.1 | 0.13 | |
| 0.23 | 0.18 | 0.15 | 96.67 | 8.14 | -13.95 | 101.96 | 37.55 | 82.79 | 15.99 | |
Total Liabilities | 152.42 | 116.98 | 78.16 | 155.87 | 189.33 | 183.31 | 209.08 | 518.9 | 425.65 | 415.91 |
Consolidated Figures in Millions / View Standalone.
| Period (M) | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| -33.32 | -34.31 | -39.33 | 39.15 | 4.88 | 16.44 | -70.12 | -81.14 | -75.62 | -0.63 | |
| -31.67 | 38.34 | 33.88 | -48.76 | 15.6 | -53.07 | -12.53 | -282.36 | 92.22 | -414 | |
| 66.78 | 1.79 | 2.19 | 8.82 | 7.52 | 24.7 | 94.82 | 356.62 | 1.08 | 415.37 | |
Net CFNet Cash Flow | 1.8 | 5.82 | -3.25 | -0.8 | 28 | -11.93 | 12.17 | -6.88 | 17.68 | 0.74 |
FCFFree Cash Flow | -33.87 | -34.67 | -39.55 | 38.84 | 4.16 | 15.6 | -70.91 | -96.55 | -94.64 | -0.63 |
Financial ratios and valuation metrics by fiscal year.
| Period | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| -30.3% | -37.0% | -52.2% | -65.3% | 27.7% | -80.8% | -137.5% | -24.5% | -39.2% | 0.1% | |
| 0.00 | - | - | - | 1.16 | 11.44 | 0.32 | 0.17 | 0.08 | - | |
| 19.54 | 9.08 | 13.11 | 3.88 | 5.46 | 2.82 | 2.95 | 8.56 | 4.27 | 8.13 | |
| 0.04 | 0.00 | 0.00 | 0.10 | 0.48 | 0.23 | 0.18 | 0.18 | 0.07 | - | |
Cash Conversion | 0.86 | 0.73 | 0.83 | -0.98 | 0.27 | -0.43 | 1.26 | 1.47 | 0.57 | -1.66 |
Payout Ratio | - | - | - | - | 0.0% | - | - | - | - | - |
| 11.8% | -100.0% | - | - | 621.4% | -48.0% | -16.1% | 80.5% | -50.3% | - | |
| - | - | - | - | - | - | - | - | - | - | |
| - | - | - | - | - | - | - | - | - | - | |
| 4.00 | 3.00 | 3.00 | 5.00 | 5.00 | 2.00 | 2.00 | 2.00 | 2.00 | 4.00 | |
| -3.06 | - | - | - | 2.94 | -5.96 | 26.02 | -0.34 | 0.35 | - | |
| 66.67 | 0.00 | 0.00 | 50.00 | 60.00 | 33.33 | 60.00 | 66.67 | 66.67 | 0.00 | |
| -6.4% | - | - | -3.5% | 0.2% | -0.9% | -1.5% | -0.9% | -4.1% | - |
Note: These ratios and scores are calculated using publicly available financial data and may differ from other sources. Users are advised to verify calculations independently using SEC filings or other official sources before making investment decisions.
Who owns ChemoCentryx Inc, from SEC filings
No SEC ownership filings for this company yet.
ChemoCentryx Inc's SEC filings and earnings call transcripts
No SEC filings for this company yet.
What recent news says about ChemoCentryx Inc, scored for sentiment.